“NattoPharma ASA recognizes that the European and Asian markets pose a huge growth potential for our science-based MenaQ7 Vitamin K2 as MK-7,” says Frode M. Bohan, chairman of the board of NattoPharma ASA, Høvik, Norway. “This opportunity requires a dedicated hand, which is why we have added Rudi De Man to our global management team. He brings a deep understanding of these markets from his nutraceutical and food ingredients background, reinforcing NattoPharma’s great expectations for the future.”
Prior to joining NattoPharma, Mr. De Man held sales leadership and business development roles where he was directly responsible for driving record growth in the FMC Health and Nutrition division, a $900M group within FMC Corporation, a $4 billion diversified chemical company. During his 19-year tenure at FMC, Mr. De Man served in a variety of sales roles with increasing responsibility, acquiring international sales experience and an extensive knowledge of the food ingredients and pharmaceutical and nutraceutical business.
Mr. De Man will be responsible for driving sales in Europe and Asia, while growing awareness of MenaQ7. He will provide technical expertise to regional partners and key accounts, identifying and developing opportunities to leverage existing proprietary MenaQ7 Vitamin K2 science and technology, and directly contributing to the company’s global strategy and growth initiatives.